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Abstract
The protein DDX3X is a DEAD-box RNA helicase that is essential for the hepatitis C virus (HCV) life cycle. The HCV core
protein has been shown to bind to DDX3X both in vitro and in vivo. However, the specific interactions between these two
proteins and the functional importance of these interactions for the HCV viral life cycle remain unclear. We show that amino
acids 16–36 near the N-terminus of the HCV core protein interact specifically with DDX3X both in vitro and in vivo.
Replication of HCV replicon NNeo/C-5B RNA (genotype 1b) is significantly suppressed in HuH-7-derived cells expressing
green fluorescent protein (GFP) fusions to HCV core protein residues 16–36, but not by GFP fusions to core protein residues
16–35 or 16–34. Notably, the inhibition of HCV replication due to expression of the GFP fusion to HCV core protein residues
16–36 can be reversed by overexpression of DDX3X. These results suggest that the protein interface on DDX3X that binds
the HCV core protein is important for replicon maintenance. However, infection of HuH-7 cells by HCV viruses of genotype
2a (JFH1) was not affected by expression of the GFP fusion protein. These results suggest that the role of DDX3X in HCV
infection involves aspects of the viral life cycle that vary in importance between HCV genotypes.
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Introduction
Hepatitis C virus (HCV) infection is a major cause of chronic
hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide
[1]. HCV is a single-strand RNA virus whose 9.6 kb genome
contains a single large translational open reading frame that
encodes a large polyprotein precursor of 3010–3033 amino acids
[2]. HCV core protein, the first structural protein encoded by the
HCV open reading frame, is a highly conserved RNA-binding
protein that forms the viral nucleocapsid [3].
To date, approximately 180 million people are infected with
HCV worldwide [4]. However, a protective vaccine is not yet
available and therapeutic options are still limited [1]. Thus,
development of new classes of antiviral compounds is urgently
needed. In the past few years, many inhibitors targeting the viral
proteins have become available [5,6]. However, for these kinds of
inhibitors, resistance to treatment will arise quickly over time, as
observed with, for example, HIV or HBV patients during therapy
[7]. On the other hand, targeting a host factor rather than a viral
protein might make it more difficult for a virus to develop
resistance against the drug [8].
DDX3X is a human RNA helicase that is ubiquitously expressed
in a wide range of tissues [9]. DDX3X has been implicated in
several cellular functions, including splicing [10,11], translation
initiationand repression [12,13], cell cycle regulation[14,15,16,17],
nucleo-cytoplasmic RNA shuttling [18], RNA transport [19],
interferon induction [20,21] and apoptosis [22]. Two separate
studies recently provided evidence for the involvement of DDX3X
in HCV replication [23,24]. Due to the finding that HIV and HCV
seem to require DDX3X for their replication [18,23], the inhibition
of DDX3X may serve as a novel therapeutic strategy for the
development of drugs against these viruses [7].
Several reports show direct interaction between HCV core
protein and DDX3X, in both cytoplasmic and nuclear compart-
ments [25,26,27]. In HCV infected cell lines, DDX3X localization
shifts from the nucleus to the cytoplasm, where it concentrates
near the endoplasmic reticulum in discrete foci. Interestingly,
DDX3X also co-localized with HCV core protein [26]. However,
the importance for a direct interaction between DDX3X and
HCV core has been questioned [28], and the exact role for this
interaction and co-localization have not been determined to date.
DDX3X can interact with the muti-component translation
initiation factor eIF3 indicating that DDX3X may play a role in
translation initiation [29]. Furthermore, eIF3 interacts with the
HCV internal ribosome entry site (IRES) in the 59-untranslated
region of the genomic RNA [30], suggesting that DDX3X may be
involved in the translation of the HCV polyprotein.
In order to determine the involvement of DDX3X in the HCV
viral life cycle, protein fusions to HCV core protein regions were
isolated that interact with DDX3X both in vitro and in vivo. These
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interactions between DDX3X and viral and cellular factors in cell-
based assays. We tested whether this kind of competition would be
sufficient to suppress maintenance of the HCV replicon or HCV
viral infectivity in HuH-7 cells.
Materials and Methods
Plasmids
A PCR product encoding the cytoplasmic domain of HCV core
protein (amino acids 1–115) was cloned into pGEX2T (Amersham
Pharmacia) to construct pGEXHCVc1-115, which encodes
glutathione-S-transferase (GST) fused in frame N-terminally to
HCV core protein residues 1–115. The plasmids expressing
related GST fusion proteins to HCV core protein segments were
constructed by using Quikchange mutagenesis (Stratagene). The
helicase domain of human protein DDX3X (amino acids 168–
582, based on DDX3X NCBI reference sequence NP_001347.3)
was cloned into pET23a (Novagen) to generate a vector encoding
the DDX3X helicase domain with an N-terminal His6 tag. HCV
core protein residues were also cloned into the vector pmaxGFP
(Amaxa) to generate N-terminal GFP fusions to truncated HCV
core proteins (Table 1). In addition, the mCherry fluorescent
protein was fused to the C-terminus of DDX3X in place of GFP,
using the same plasmid background. The resulting mammalian
expression vectors utilize the CMV transcription promoter. All
plasmid sequences were confirmed by DNA sequencing.
In vitro interaction of HCV core protein fragments with
DDX3X
Interactions between the DDX3X helicase domain and HCV
core protein fusion peptides were assayed using GST pull-downs
(ProFound, Pierce). Briefly, E. coli BL21 cells carrying expression
plasmids (Table 1) were treated with 0.3 mM isopropyl-b-D-
thiogalactopyranoside (IPTG) to induce fusion protein expression.
The bacterial cells were harvested, pelleted, and resuspended in
1 mL of phosphate buffered saline (PBS) per 5 mL of bacterial
culture. The cells were then disrupted by sonication on ice. Triton
X-100 was added to a final concentration of 0.01%, and proteins
were purified using glutathione-Sepharose resin (GE Healthcare).
Purified GST fusion proteins (1 mM in 1 mL) were mixed gently
with 0.1 mL reduced glutathione-Sepharose 4B beads (GE
Healthcare) for 60 min at 4uC. The beads were collected by brief
centrifugation and washed three times with PBS containing 0.01%
Triton X-100. Purified DDX3X helicase domain (3 mM) was
added to the beads in a volume of 1 mL and incubated for 3 h at
20uC with gentle rotation. The beads were washed 3 times with
PBS containing 0.01% Triton X-100 per wash. Proteins bound to
the beads were eluted in sodium dodecyl sulfate-polyacrylamide
(SDS-PAGE) sample buffer, fractionated by SDS-PAGE (10%
polyacrylamide gel) and stained by Coomassie blue.
In vitro binding of GST-HCV core fusion proteins to
endogenous DDX3X
HCV core protein fragments expressed as GST fusions from the
pGST expression vectors (Table 1) were purified as described
above. For in vitro binding assays, 0.1 mL of glutathione-Sepharose
4B beads (GE Healthcare) containing various GST fusion proteins
(10 mg) were incubated with HuH-7 cell extracts (500 mg) at 4uC
overnight with gentle rotation [27]. The beads were washed four
times with 1 mL of PBS containing 0.01% Triton X-100 per wash.
Proteins bound to the beads were eluted by SDS-PAGE sample
buffer, fractionated by SDS-PAGE (10% polyacrylamide gel) and
processed for Western blot analysis. The separated proteins were
Table 1. Plasmids used in this study.
Plasmids Description Reference or source
pGEX2T 4.97 kb, IPTG-inducible expression vector for GST fusion Amersham Pharmacia
pGEXHCVc1-115 pGEX2T derived expression plasmid for HCV core (aa 1–115) This study
pGEXHCVc1-34 pGEX2T derived expression plasmid for HCV core (aa 1–34) This study
pGEXHCVc1-35 pGEX2T derived expression plasmid for HCV core (aa 1–35) This study
pGEXHCVc1-36 pGEX2T derived expression plasmid for HCV core (aa 1–36) This study
pGEXHCVc11-36 pGEX2T derived expression plasmid for HCV core (aa 11–36) This study
pGEXHCVc16-34 pGEX2T derived expression plasmid for HCV core (aa 16–34) This study
pGEXHCVc16-35 pGEX2T derived expression plasmid for HCV core (aa 16–35) This study
pGEXHCVc16-36 pGEX2T derived expression plasmid for HCV core (aa 16–36) This study
pGEXHCVc21-36 pGEX2T derived expression plasmid for HCV core (aa 21–36) This study
pET23a 3.66 kb IPTG-inducible expression vector with His6 tag Novagen
pETDDX3X168-582 pET23a derived expression plasmid for DDX3X (aa 168–582) This study
pmaxGFP 3.48 kb mammalian GFP expression vector Amaxa
pGFPHCVc16-34 pmaxGFP derived expression plasmid for HCV core (aa 16–34) This study
pGFPHCVc16-35 pmaxGFP derived expression plasmid for HCV core (aa 16–35) This study
pGFPHCVc16-36 pmaxGFP derived expression plasmid for HCV core (aa 16–36) This study
pmCherry-N1 4.72 kb mCherry expression vector for C-terminal fusions Clontech
pDDX3XmCherry Expression plasmid for mCherry C-terminal fusion to full length DDX3X This study
pcDNA3 5.4 kb mammalian expression vector Invitrogen
pDiLuc pcDNA3 derived plasmid expressing cap-dependent Renilla luciferase and HCV
IRES-dependent Firefly luciferase
This study
doi:10.1371/journal.pone.0012826.t001
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(Roche). After blocking for 1 h with 5% nonfat milk, the
membranes were probed with primary antibody, washed with
TBST (125 mM NaCl; 25 mM Tris pH 8.0; 0.1% Tween-20) 3
times, 10 min/per wash, and then incubated with horse radish
peroxidase (HRP) labeled IgG (ProSci Incorporated, USA; 1:5,000
final dilution). Unbound antibody was removed by washing and
the blots were developed using a LumiBlot detection kit (Novagen,
USA). Detection of DDX3X was performed with rabbit anti-
DDX3X antiserum (ProSci Incorporated; 1:1,000).
Co-immunoprecipitation
Immunoprecipitation was performed essentially as described
[31], with minor modifications. After transient transfection of
HuH-7 cells (described below), the growth medium was removed
and the cells were rinsed twice in cold phosphate-buffered saline,
incubated for 30 min at 4uC in lysis buffer (50 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol,
0.2 mM phenylmethylsulfonyl fluoride, and 1% NP-40), and
collected by scraping. Cell debris was removed by centrifugation at
10,0006g for 10 min at 4uC. Extracts were precleared with
Figure 1. Pull-down assays of HCV core derived peptides and DDX3X helicase domain (DDX3Xh). (A). Schematic of the different GST
fusions to the N-terminal fragments of the HCV core protein. Also shown is a schematic of DDX3X, with the DEADc and HELICc domains of the DEAD-
box helicase labeled. (B). Schematic diagram of the regions of HCV core protein interacting with the DDX3X helicase domain (DDX3Xh) in pull-down
assays. (C). Analysis of the interaction between DDX3Xh, GST or various GST fusions to HCV core proteins. Glutathione beads were used to pull down
bound proteins prior to SDS gel electrophoresis. Lanes 1–4, GST fusions to the denoted HCV peptides incubated with DDX3Xh. Lane 5, DDX3Xh
marker. Molecular weight markers are shown to the left, in kDa.
doi:10.1371/journal.pone.0012826.g001
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antibody of GFP (Evrogen, 1:30,000) was added for 1 h at 4uC,
and immunoglobulin complexes were incubated with protein G-
agarose beads for 1 h at 4uC. The beads were extensively washed
and analyzed by immunoblotting using the specific antibody
against DDX3X as described above. For the detection of the GFP
or GFP fusion HCV core proteins, rabbit anti-GFP antibody
(Evrogen; 1:30,000) was used.
Cell culture, transfection and reporter assays
For HCV replication studies, a stable HuH-7 cell line
containing HCV genotype 1b strain N genomic replicon NNeo/
C-5B (hereafter named cell line 5B) was used [32]. The cell line
was routinely grown in DMEM media supplemented with
nonessential amino acids, penicillin, streptomycin, and 10% FBS
(Omega Scientific) as described previously [32]. As indicated,
500 mg/mL G418-active ingredient (Geneticin, GIBCO Invitro-
gen) was added into the medium.
For inhibitory assays, cell line 5B was transfected with plasmids
encoding GFP alone or encoding N-terminal GFP fusions to HCV
core peptides using FuGENE 6 (Roche). Briefly, about 3610
5 5B
cells/10 mL medium were plated into each 10 cm plate 1 day
prior to transfection. For each transfection, up to 6 mg of DNA was
mixed with 18 mL of FuGENE 6 reagent diluted in 600 mLo f
Optimem media (Gibco BRL) and incubated for 20 min at room
temperature. The DNA–FuGENE solution was then added
directly to the cells. After 48 h, the cells were collected and split
into two parts, one part for Northern blotting and the other for
Western blot analysis. Transfection efficiency was assayed using
FACS analysis in a C6 Flow Cytometer (Accuri Cytometers Inc.,
USA), and varied between 70%–100% (Figure S1).
For DDX3X overexpression assays, 3 mg of plasmids encoding
GFP or GFP fusions to HCV core peptides (pmaxGFP,
pGFPHCVc16-35, pGFPHCVc16-36) and 3 mg of plasmids
encoding mCherry (pmCherry) or mCherry fusions to DDX3X
(pDDX3XmCherry) were co-transfected into 3610
5 5B cells.
Forty-eight hours after transfection, the cells were collected and
split into two parts, one part for Northern blotting and the other
for Western blot analysis.
For the luciferase activity inhibitory assays, 3 mg of plasmids
encoding GFP or GFP fusions to HCV core peptides (pmaxGFP,
pGFPHCVc16-35, pGFPHCVc16-36) and 1 mg plasmid pDiluc
encoding the cap-dependent Renilla luciferase and HCV IRES-
dependent Firefly luciferase were co-transfected into 3610
5 5B
cells. Forty-eight hours after transfection, the cells were collected
and split into three parts, one part for Northern blotting, the
second for Western blotting and the third for luciferase activity
analysis. A Dual-luciferase reporter system was used for luciferase
activity analysis (Promega). In DDX3X rescue experiments, 3 mg
of plasmid encoding mCherry or DDX3X-mCherry fusions
(pmCherry-N1 or pDDX3XmCherry) were also included in the
co-transfections.
Western blot analysis of fusion protein expression in
transiently transfected 5B cells
HuH-7 cells harboring the HCV replicon transiently transfected
with plasmids pGFPHCVc16-35 or pGFPHCVc16-36, as de-
scribed above, were assayed for HCV core peptide fusion protein
expression by Western blot. The DDX3X and mCherry fusions to
DDX3X were detected by a rabbit anti-DDX3X antibody (ProSci
Incorporated; 1:1,000). The rabbit anti-actin antibody (Sigma;
1:1,000) was used to detect actin as the loading control.
Northern blot analysis
Total cellular RNAs were extracted from HuH-7 cells by using
the TRIzol reagent (Gibco-BRL) and were quantified using a
Nanodrop spectrophotometer (Thermo Scientific) at 260 nm. The
resulting total cellular RNA samples (10 mg) were denatured and
fractionated by agarose gel [33]. The RNA was transferred from
the gel to a nylon membrane by using 10 x SSC (1.5 M NaCl,
0.15 M Sodium Citrate), and immobilized on the membrane by
UV cross-linking (Stratagene).
For monitoring HCV replicon expression, b-actin mRNA levels
were used as an internal control in the Northern blot analyses as
described [34]. DNA probes specific to the HCV replicon RNA
and b-actin were [
32P]-labeled using a RadPrime DNA labeling
system (Invitrogen). For the detection of mRNA transcript
integrity for luciferase assays, a probe spanning the 39 120
nuclueotides of the Renilla luciferase open reading frame (ORF)
through the 59 126 nucleotides of the Firefly luciferase ORF was
labeled as described above. Hybridization was carried out in
ExpressHyb solution (CloneTech) for 1 h at 65uC. The membrane
was washed 3610 min at 55uC with 0.1 x SSC/0.1% SDS. Band
intensities on the probed membranes were quantified by STORM
phosphorimager analysis (Molecular Dynamics).
Figure 2. Interaction of DDX3X with HCVc16-36 in vitro and in
vivo. (A). In vitro binding analysis of endogenous DDX3X and the
various truncated forms of HCV core proteins. Western blot of GST or
GST fusions to the denoted HCV core peptides incubated in HuH-7 cell
lysate, pelleted using glutathione beads, and resolved by SDS gel
electrophoresis. Lane 1, HuH-7 cell lysate input. Lanes 2–4, GST pull-
down experiments. (B). Co-immunoprecipitation of GFP fusions to HCV
core peptides and DDX3X from co-transfected HuH-7 cells. Immuno-
precipitates were analysed by sequential immunoblotting with anti-
DDX3X and anti-GFP antibodies. Lane 1, DDX3X marker from HuH-7 cell
lysate. Lanes 2–4, co-immunoprecipitations of GFP fusions to the
denoted HCV peptides using anti-GFP antibodies.
doi:10.1371/journal.pone.0012826.g002
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Two protocols were applied to examine the effect of GFP-
HCV core expression on JFH1 infection. In protocol one, HuH-7
cells were seeded in 6 cm culture plates and then transfected
with 4 mg total plasmid DNA and FuGENE6, according to the
manufacturer’s specifications. Specifically, 0.25 mg pmaxGFP,
1 mg pGFPHCVc16-34, 4 mg pGFPHCVc16-35, and 2 mg
pGFPHCVc16-36 and varying amounts of pcDNA3 (to yield
4 mg DNA) were transfected. Twenty-four hours after transfection,
cells were infected with JFH1 virus for 5 h at 37uC. Infected cells
were then trypsinized and re-seeded into two 10 cm culture plates.
Protein and RNA extracts were harvested three days after
infection. In protocol two, HuH-7 cells were seeded in a 10 cm
culture dish and infected with JFH1 virus for 5 h at 37uC,
trypsinized and re-plated into five 10 cm culture dishes. Two days
after infection, cells were transfected with 8 mg total plasmid DNA
Figure 3. Effects of HCVc16-36 on HCV replicon RNA abundance. (A). Diagram of the HCV replicon NNeo/C-5B (30) used in the experiment.
The plasmid encodes the 59-UTR of genotype 1b HCV-N immediately upstream of the sequence encoding the N-terminal 12 amino acids of the core
protein fused in-frame to the selectable marker, Neo. The Neo gene is followed by the IRES of EMCV fused to the full genotype 1b HCV-N polyprotein
sequence and 39-UTR (30). (B). Northern blot analysis of HCV replicon RNA remaining in HuH-7 cells 48 h after transient transfection with GFP fusion
protein encoding plasmids: pmaxGFP, pGFPHCVc13-35 (HCVc16-35), and pGFPHCVc16-36 (HCVc16-36). Northern blots of actin mRNA levels serve as a
loading control. Duplicate experiments are shown in lanes 1–2, 3–4, and 5–6. (C). Quantification of HCV replicon RNA from panel B. Experiments were
carried out in duplicate and columns represent the quantity of HCV RNA, normalized to b-actin mRNA, and to the levels in pmaxGFP transfected cells.
Error bars represent the standard deviation from the mean for the experiments. (D). Expression of GFP fusions to N-terminal fragments of the HCV
core protein. HuH-7 cells were transiently transfected with plasmids encoding the GFP fusions, and the fusion proteins were detected 48 h post-
transfection by Western blotting with an anti-GFP antibody. Western blots of actin serve as loading controls.
doi:10.1371/journal.pone.0012826.g003
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follows: 0.5 mg pmaxGFP, 2 mg pGFPHCVc16-34, 8 mg
pGFPHCVc16-35, and 4 mg pGFPHCVc16-36 and varying
amounts of pcDNA3 (to yield a total of 8 mg DNA). Cells were
harvested 24 h later and levels of protein and RNA were analyzed
by Western and Northern blot, respectively.
Results
HCV core peptides interact specifically with DDX3X
in vitro and in vivo
The domain of HCV core that interacts with DDX3X was
originally mapped to the N-terminal 40 amino acids of the HCV
core protein [27]. To determine the minimal requirements for
specific HCV core peptide binding to DDX3X, a series of N-
terminal GST fusions to HCV core peptides were used for pull-
down assays (Figure 1B). The results showed that amino acids 1–
15 (Figure 1B) and 37–40 (data not shown) were not necessary for
the interaction with DDX3X helicase domain. Thus, HCV core
peptides including amino acids 16 to 36 are sufficient for binding
to the DDX3X helicase domain (Figure 1B, C). In contrast, HCV
core peptides that include even one less residue, i.e. amino acids
16–35, did not bind to the DDX3X helicase domain (Figure 1B,
C). Notably, the backbone of position 36, but not the sequence, is
essential for binding of the core peptide to DDX3X (Figure
S2)[28]. Additionally, when the GST-HCV core fusion peptides
were used for pull-down assays with endogenous DDX3X from
HuH-7 cells, the same specificity of binding was observed
(Figure 2A).
To determine whether peptides from HCV core protein
containing amino acids 16–36 are capable of binding to DDX3X
in cells, HuH-7 cells were transiently transfected with vectors that
express GFP or GFP fusions to HCV core peptides from amino
acids 16–36 or 16–35. When cell lysates from transfected HuH-7
cells were immunoprecipitated by an anti-GFP antibody, Western
blots revealed that DDX3X co-immunoprecipitated with the GFP
fusion to HCV core peptide residues 16–36 (Figure 2B). In
contrast, GFP fusions to HCV core peptides containing residues
16–35 did not co-immunoprecipitate with DDX3X (Figure 2B).
These results indicate that the HCV core peptide containing
residues 16–36 bound specifically to DDX3X in HuH-7 cells,
consistent with the in vitro assays with purified proteins.
HCVc16-36 inhibits the replication of a genotype 1b-
derived HCV replicon
Since HCV core peptides containing residues 16–36 are capable
of binding DDX3X in cells, and given the importance of DDX3X
for HCV viral infectivity [23,24], it is possible that expression of
these HCV core peptides might block DDX3X interactions with
cellular or viral factors that are required during the viral life cycle.
To test whether HCV core peptides could inhibit HCV
replication, GFP fusions to HCV core peptides were transiently
expressed in HuH-7 cells harboring the NNeo/C-5B HCV
replicon derived from HCV genotype 1b (Figure 3A). When the
HuH-7 cells were transiently transfected with plasmids encoding a
GFP fusion to HCV core protein amino acids 16-36, the levels of
the HCV replicon RNA dropped by 50% after 48 h (Figures 3B,
C). Stable transfection of a plasmid encoding a GST fusion to
Figure 4. Inhibition of cap- and HCV IRES-dependent transla-
tion by HCVc16-36. (A). Schematic of the pDiLuc plasmid, and the
effects of expression of GFP fusions to HCV core peptides on cap- and
HCV IRES-dependent luciferase expression in 5B cells. RLuc, Renilla
luciferase; FLuc, Firefly luciferase. (B). Northern blot analysis of the
dicistronic luciferase mRNA from cells transfected with plasmids
encoding GFP or GFP fusions to HCV core peptides (HCVc16-35 and
HCVc16-36) and dicistronic luciferase vectors. (C). Western blot analysis
of the expression of GFP fusions to HCV core peptides of the samples
used in panels A and B. (D). Partial rescue of activities of cap- and HCV
IRES-dependent luciferases repressed by the HCVc16-36. Co-expression
of mCherry in controls is compared to co-expression of DDX3X-
mCherry.
doi:10.1371/journal.pone.0012826.g004
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levels of HCV replicon RNA after several days of cell culture (data
not shown). Notably, no inhibition was observed when cells were
transiently or stably transfected with plasmids that encoded a GFP
or GST fusion to the fragment of the HCV core protein
comprising amino acids 16–35 (Figures 3B, C).
To determine the possible mechanism by which maintenance of
the NNeo/C5-B replicon in HuH-7 cells was suppressed, HCV
core peptide fusions were transiently transfected into HuH-7 cells
expressing luciferase. The activities of cap-dependent and HCV
IRES-dependent luciferases were repressed by the expression of
GFPHCVc16-36 compared to the expression of GFP and
Figure 5. Rescue of HCV replicon RNA by DDX3X in HuH-7 cells. (A). Northern blot of HCV replicon RNA levels in cells expressing GFP fusions
to HCV core peptides (HCVc16-35, HCVc16-36) in the absence (mCherry) or presence of exogenously expressed DDX3X fused to mCherry (DDX3X-
mCherry). (B). Quantification of the HCV replicon RNA levels in panel A. Experiments were done in duplicate and columns represent the percentage of
HCV replicon RNA normalized to b-actin mRNA levels. (C). Western blot analysis of the expression of DDX3X and GFP fusions to HCV core peptides in
the samples used in panel A.
doi:10.1371/journal.pone.0012826.g005
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level of translation but not at the level of transcription because
overall reporter RNA abundance was not affected (Figure 4B).
Notably, inhibition of luciferase expression by HCV core peptides
could be rescued by overexpression of DDX3X (Figure 4D),
supporting the hypothesis that HCVc16-36 interacts with DDX3X
in vivo.
In order to examine whether the decrease in HCV replicon
RNA is due to inhibition of endogenous DDX3X activity, vectors
encoding the mCherry fusion to DDX3X as well as the GFP
fusions to HCV core peptides were transfected into the HuH-7
cells harboring the NNeo/C-5B replicon. Expression of GFP
fusions to HCV core peptide residues 16-36 reduced replicon
RNA levels when mCherry alone was co-transfected (Figures 5A
and B). However, the HCV core peptide fusion did not decrease
viral RNA abundance when the cells expressed both the GFP-
HCV core peptide fusion and mCherry fused to DDX3X
(Figures 5A and B). In fact, the expression of exogenous DDX3X
in the cells slightly increased the amount of the HCV replicon
(Figure 5B).
HCV core peptides do not inhibit HCV virus JFH1
infection of HuH-7 cells
HCV replicons recapitulate some but not all aspects of the
HCV viral life cycle. In order to test whether the effect of HCV
core peptide expression could decrease HCV viral infectivity more
broadly, HuH-7 cells were assayed for JFH1 HCV infection in two
different ways. In one experiment, HuH-7 cells were first
transiently transfected with vectors encoding the GFP-HCV core
protein fusions, and then infected with the JFH1 virus. Three days
after infection, the cells were harvested and HCV viral RNA and
NS5A protein levels were analyzed. In these experiments,
expression of HCV peptides had no appreciable effect on the
levels of HCV RNA and protein, although levels of GFP fusion
protein expression were similar (Figure 6). In another experiment,
HuH-7 cells were first infected with JFH1 virus. Two days after
infection, the cells were transfected with vectors encoding the GFP
fusions to HCV core peptides. As in the first experiment,
expression of fusions to HCV core peptides had no discernible
effect on HCV viral RNA or NS5A protein levels (Figure 7).
Discussion
The high prevalence of disease caused by HCV and the limited
efficacy of interferon-based therapies have stimulated the search
for safer and more effective drugs to treat HCV infection [35]. In
the past few years, more and more inhibitors targeting the viral
protease and polymerase had been developed [5]. Recently, new
compounds have been discovered that target HCV protein NS5A
[6]. However, resistance to these kinds of inhibitors has been
problematic. One possible solution to the buildup of resistance
mutations in the virus is to target host cellular factors.
Theoretically, a drug that targets a cellular factor that is important
for the viral life cycle could generally inhibit all viruses that depend
on the same host factor [7]. Given that DDX3X seems to be
required for replication of HCV and HIV, it appears that DDX3X
could be a promising target for drug development against these
two viruses that pose major global health threats [7].
It was recently shown that DDX3X is required for HCV RNA
replication, with infectious virus production strongly inhibited [24]
and HCV replicon stability partially suppressed by DDX3X
knock-downs [23]. These results indicate that DDX3X plays a
crucial role in the HCV life cycle. HCV core protein interactions
with DDX3X could be important for this effect. In order to disrupt
possible interactions between DDX3X and its viral or host factors
responsible for DDX3X stimulation of HCV propagation, we first
mapped the minimal segment of HCV core protein that is capable
of interacting with DDX3X. The interaction domain of HCV core
to the DDX3X was originally mapped to the N-terminal 40 amino
acids of the HCV core protein [27]. Based on this result, we
mapped the minimal interaction region of HCV core, both in vitro
and in vivo, to include amino acids 16 to 36 (Figure 1, Figure 2). We
then overexpressed fusions to HCV core protein residues 16-36 to
test their ability to suppress HCV replicon maintenance or HCV
viral infectivity. These fusions did act as competitors for DDX3X
by suppressing NNeo/C5-B replicon maintenance (Figure 3),
Figure 6. HCV protein and RNA abundances in HuH-7 cells
expressing GFP-Core fusion proteins, following infection with
JFH1 virus. HuH-7 cells were transfected with pGFP-Core plasmids
(pGFPHCVc16-34, pGFPHCVc16-35, pGFPHCVc16-36), infected with
JFH1 virus and harvested three days after infection. (A) HCV and GFP
protein levels were examined in Western blots using anti-NS5A MAb
9E10, anti-GFP and anti-Actin antibodies. (B) HCV and actin RNA levels
were analyzed in Northern blots.
doi:10.1371/journal.pone.0012826.g006
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Furthermore, suppression of HCV replicon maintenance by the
fusions had the same core peptide length dependence seen for
binding to DDX3X.
Interestingly, a recent report using a JFH1-based replicon
showed that the interaction between the HCV core protein and
DDX3X is not required for HCV replicon maintenance [28],
seemingly in contradiction with our results with the NNeo/C-5B
replicon. It is possible that HCV genotypic differences between
JFH1 viruses (genotype 2a) and the NNeo/C-5B replicon
(genotype 1b) are the reason for the differences seen here.
Notably, the only sequence difference in the two genotypes within
core protein residues 16-36 occurs at position 20, a position that is
not important for interactions with DDX3X (Figure S3) [28]. It is
possible that the potency of the peptides as competitors are not
strong enough to be detected in the context of JFH1 viruses. It is
known that JFH1 replicons exhibit a higher efficiency of HuH-7
colony formation when compared to genotype 1b (HCV-N-
derived) replicons such as NNeo/C5-B, even though their
replicating RNA copy numbers are similar [36]. Furthermore,
JFH1–based replicons were found to be more resistant to
interferon than HCV-N-based replicons such as NNeo/C5B
[36]. We propose that the fusions to the HCV core peptides used
in the present studies block a protein interaction interface on
DDX3X that is important for binding viral or host factors involved
in HCV replication. While it is probable that the HCVc16-36 core
peptide competes with direct interactions between HCV core and
DDX3X [25,26,27], interference with DDX3X binding to other
viral or host factors could be more important [28].
In the present experiments, HCV core-derived peptides
containing amino acids 16-36 can bind DDX3X and thereby
inhibit HCV NNeo/C5-B replicon maintenance in HuH-7 cells.
Thus, the HCV core peptide identified here could serve as a
potential inhibitor of HCV that targets a cellular protein factor
[37]. It will be interesting in future experiments to unravel the
many potential functions of DDX3X that may be involved in the
HCV viral life cycle [8], and how interactions of the HCV core
peptides used here inhibit these functions of DDX3X. A long-
range goal would be to improve the potency of competitors that
bind to DDX3X and specifically block its function in the viral life
cycle of multiple HCV genotypes.
Supporting Information
Figure S1 FACS analysis of GFP-HCV core fusion transfection
efficiency. Histograms of cell number versus GFP fluorescence are
shown for an empty vector (pmaxGFP without gfp gene), GFP
expression vector (pmaxGFP), or vectors expressing GFP fusions to
HCV core peptides 16-35 (pGFPHCVc16-35) or 16-36
(pGFPHCVc16-36). Transfection efficiencies listed below each
panel are estimated based on comparisons to the empty vector
control.
Found at: doi:10.1371/journal.pone.0012826.s001 (0.35 MB TIF)
Figure S2 Pull-down assays of HCV core derived peptides with
mutations at position 36 and DDX3X helicase domain
(DDX3Xh). Analysis of the interaction between DDX3Xh, GST
or various GST fusions to HCV core proteins mutated at position
36. Glutathione beads were used to pull down bound proteins
prior to SDS gel electrophoresis. Lanes 2–6, GST fusions to the
denoted HCV peptides incubated with DDX3Xh. Lanes 1 and 7,
GST and DDX3Xh markers, respectively. Molecular weight
markers are shown to the left, in kDa.
Found at: doi:10.1371/journal.pone.0012826.s002 (0.49 MB TIF)
Figure S3 Pull-down assays of HCV core derived peptides
mutated at position 20 and DDX3X helicase domain (DDX3Xh).
Analysis of the interaction between DDX3Xh, GST or GST
fusions to HCV core peptides. Glutathione beads were used to pull
down bound proteins prior to SDS gel electrophoresis. Lanes 2–3,
GST fusion to the denoted HCV peptides incubated with
DDX3Xh. Lanes 1 and 4, GST and DDX3Xh markers,
respectively. All samples were resolved on the same SDS gel, with
intervening lanes removed for clarity. Molecular weight markers
are shown to the left, in kDa.
Found at: doi:10.1371/journal.pone.0012826.s003 (0.18 MB TIF)
Figure 7. HCV protein and RNA abundances in HuH-7 cells after
infection with JFH1 virus, followed by transfection of plasmids
encoding GFP and GFP-Core peptides. HuH-7 cells were infected
with JFH1 virus. Two days after infection cells were transfected with
pGFP-Core plasmids (pGFPHCVc16-34, pGFPHCVc16-35, pGFPHCVc16-
36). (A) HCV and GFP-Core fusion protein levels were examined in
Western blots using anti-NS5A MAb 9E10, anti-GFP and anti-Actin
antibodies. (B) HCV and actin RNA levels were analyzed in Northern
blots.
doi:10.1371/journal.pone.0012826.g007
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